Suppr超能文献

遗传学在肥厚型心肌病诊断与管理中的作用:展望未来

Role of Genetics in Diagnosis and Management of Hypertrophic Cardiomyopathy: A Glimpse into the Future.

作者信息

Abbas Mohammed Tiseer, Baba Ali Nima, Farina Juan M, Mahmoud Ahmed K, Pereyra Milagros, Scalia Isabel G, Kamel Moaz A, Barry Timothy, Lester Steven J, Cannan Charles R, Mital Rohit, Wilansky Susan, Freeman William K, Chao Chieh-Ju, Alsidawi Said, Ayoub Chadi, Arsanjani Reza

机构信息

Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Biomedicines. 2024 Mar 19;12(3):682. doi: 10.3390/biomedicines12030682.

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. It follows an autosomal dominant inheritance pattern in most cases, with incomplete penetrance and heterogeneity. It is familial in 60% of cases and most of these are caused by pathogenic variants in the core sarcomeric genes (, , , , , , , ). Genetic testing using targeted disease-specific panels that utilize next-generation sequencing (NGS) and include sarcomeric genes with the strongest evidence of association and syndrome-associated genes is highly recommended for every HCM patient to confirm the diagnosis, identify the molecular etiology, and guide screening and management. The yield of genetic testing for a disease-causing variant is 30% in sporadic cases and up to 60% in familial cases and in younger patients with typical asymmetrical septal hypertrophy. Genetic testing remains challenging in the interpretation of results and classification of variants. Therefore, in 2015 the American College of Medical Genetics and Genomics (ACMG) established guidelines to classify and interpret the variants with an emphasis on the necessity of periodic reassessment of variant classification as genetic knowledge rapidly expands. The current guidelines recommend focused cascade genetic testing regardless of age in phenotype-negative first-degree relatives if a variant with decisive evidence of pathogenicity has been identified in the proband. Genetic test results in family members guide longitudinal clinical surveillance. At present, there is emerging evidence for genetic test application in risk stratification and management but its implementation into clinical practice needs further study. Promising fields such as gene therapy and implementation of artificial intelligence in the diagnosis of HCM are emerging and paving the way for more effective screening and management, but many challenges and obstacles need to be overcome before establishing the practical implications of these new methods.

摘要

肥厚型心肌病(HCM)是最常见的遗传性心肌病。在大多数情况下,它遵循常染色体显性遗传模式,具有不完全外显率和异质性。60%的病例为家族性,其中大多数是由核心肌节基因( 、 、 、 、 、 、 )中的致病变异引起的。强烈建议对每例HCM患者进行基因检测,使用利用下一代测序(NGS)的靶向疾病特异性检测板,其中包括关联证据最充分的肌节基因和综合征相关基因,以确诊、确定分子病因并指导筛查和管理。散发性病例中致病变异的基因检测阳性率为30%,家族性病例以及典型非对称性室间隔肥厚的年轻患者中该阳性率高达60%。基因检测在结果解释和变异分类方面仍然具有挑战性。因此,2015年美国医学遗传学与基因组学学会(ACMG)制定了指南来对变异进行分类和解释,强调随着遗传学知识迅速扩展,有必要定期重新评估变异分类。当前指南建议,如果在先证者中鉴定出具有决定性致病证据的变异,则对表型阴性的一级亲属无论年龄进行重点级联基因检测。家庭成员的基因检测结果可指导长期临床监测。目前,有新证据表明基因检测可应用于风险分层和管理,但其在临床实践中的实施尚需进一步研究。基因治疗和人工智能在HCM诊断中的应用等有前景的领域正在兴起,为更有效的筛查和管理铺平道路,但在确立这些新方法的实际意义之前,还需要克服许多挑战和障碍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9da/10968563/04a39ebd7f44/biomedicines-12-00682-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验